Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 22, 2026

Crypto News: Pepeto Announces Exchange Upgrade While XRP Price Prediction Targets New ATH and Trump Iran War Shakes Crypto Markets

View original at globenewswire.com
Crypto News: Pepeto Announces Exchange Upgrade While XRP Price Prediction Targets New ATH and Trump Iran War Shakes Crypto Markets Dubai, UAE, March 22, 2026 (GLOBE NEWSWIRE) -- The Pepeto team just announced a new security upgrade on the exchange, adding stronger AI checks on the bridge and swap tools that work across…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • $466 million in trades went into forced closing across the crypto market after Trump threatened strikes on Iranian oil

    60% confidence

  • War spending and oil problems raise the chance of rate cuts, and rate cuts are the one thing that has started every crypto bull run in history

    60% confidence

  • BTC has made a higher low after every war headline since the fighting started

    60% confidence

  • Goldman Sachs is adding to its XRP position

    60% confidence

  • Ripple spent $2.4 billion on deals over the past year that built the kind of setup big money needs to come in

    60% confidence

  • Analysts see $5 as the floor target for XRP and some go as high as $10 once the CLARITY Act passes its March 27 review and ETF money has a clear path to enter

    60% confidence

Data points we hold from this source

XRP · daily transactions2.7 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Crypto News: Pepeto Announces Exchange Upgrade While XRP Price Prediction Targets New ATH and Trump Iran War Shakes Crypto Markets — Source | Via News | ViaNews Market